Co-founded by researchers Joseph Glorioso, from the University of Pittsburgh’s microbiology and molecular genetics department; and Dr. Nicholas Boulis, the founder of Emory’s Gene and Cell Therapy for Neurorestoration Laboratory; Coda uses gene therapies to treat neurological diseases starting with severe pain and epilepsy.
And over the past twenty years the doctors treating those Americans and the drug companies developing therapies for them have managed to turn their treatment into a new epidemic — opioid addiction.
Coda’s experimental treatment is based on a science called chemogenetics, which uses a harmless virus to create new receptors in the sensory neurons that provide signals to the brain about physical stimuli.
We’ve engineered it so that it is no longer responsive,” says Michael Narachi, the president and chief executive officer at Coda.
By engineering neurotransmitter receptors that are activated by medicines that can be taken orally, Coda thinks it can control the activity of neurons responsible for both chronic pain and focal epilepsy.
The next step for the company — and part of the use of proceeds from its new $15 million cash infusion — will .